Walgreens appoints new chief marketing officer
DEERFIELD, Ill. Walgreens has tapped a new vice president and chief marketing officer, Kim L. Feil, the company announced Thursday.
Feil brings to the Walgreens marketing team 25 years of marketing, planning and sales experience. Prior to her new post, she served at Sara Lee as senior vice president and chief marketing officer. Before Sara Lee, Feil held post at Kimberly-Clark as vice president and senior marketing officer.
“Under Kim’s direction, our marketing folks will enhance the in-store customer experience and create stronger connections to our online offerings and Take Care Clinic services,” Walgreens president Greg Wasson said in a statement. “Kim brings a strong consumer research and marketing background to us at a time when deep understanding of customers is critical. From her previous experience, she offers a valuable and unique perspective in collecting and leveraging consumer insights.”
Feil has also spent seven years at Chicago-based research tank Information Resources Inc. She’s also held posts at PepsiCo and Cadbury Schweppes.
Unapproved eye treatments get yanked by FDA
NEW YORK The Food and Drug Administration has told companies to stop selling eye solutions for use during surgery and for treating lesions without regulatory approval, citing dangerous side effects.
The drugs include ophthalmic balanced salt solutions for the eyes and topical drugs containing the papaya-based compound papain.
A number of companies have sold the unapproved eye drugs, including Baxter International and Hospira.
ImClone rejects bid from Bristol-Myers Squib
NEW YORK Biotech ImClone has rejected an acquisition bid by Bristol-Myers Squibb, according to a letter that ImClone chairman Carl Icahn sent to Bristol chairman and chief executive officer James Cornelius Tuesday, calling the bid “absurd.”
On Monday, Bristol announced that it would increase its $60-per-share bid for the biotech to $62 a share, though this still fell short of the $70-per-share offer that ImClone has received from a thus-far undisclosed pharmaceutical company.
“Your letter of yesterday contains inaccuracies which are misleading to our shareholders,” Icahn wrote. “Your statements that there have not been any meaningful discussions concerning your proposal have no basis in fact. … I also told you a large Pharma company had offered $70 subject to due diligence and the diligence will be over on Sunday, September 28, 2008. In light of these facts, your hostile tender of $62, at this time, seems absurd.”
At the end of the letter, Icahn didn’t mince words.
“If you wish to make your attorneys wealthier, I can show you more productive ways to do so,” he wrote. “Or, if you simply want publicity, I can also help you in that regard without your having to make unnecessary expenditures.”